Home
Live Updates
First Patient Dosed in Phase II IPAX-Linz Study of TLX101 for Glioblastoma Therapy : comparemela.com
First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy
MELBOURNE, Australia, Nov. 21, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first pati...
Related Keywords
Australia ,
Japan ,
United States ,
United Kingdom ,
Belgium ,
Austria ,
Melbourne ,
Victoria ,
Canada ,
Switzerland ,
Australian ,
Ordensklinikum Linz ,
Kyahn Williamson ,
Colin Hayward ,
Barmherzige Schwestern ,
Josef Pichler ,
Christian Behrenbruch ,
Telix Pharmaceuticals ,
Linkedin ,
Kepler University Hospital ,
Kepler University Hospital In Linz ,
Drug Administration ,
Australian Securities Exchange ,
Australian Therapeutic Goods Administration ,
Corporate Communications ,
Telix Pharmaceuticals Limited ,
Health Canada ,
Professor Josef Pichler ,
Principal Investigator ,
Chief Medical Officer ,
Managing Director ,
Group Chief Executive ,
comparemela.com © 2020. All Rights Reserved.